{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T22:28:22Z","timestamp":1789597702764,"version":"build-2803163510"},"reference-count":131,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.clml.2018.02.005","type":"journal-article","created":{"date-parts":[[2018,2,7]],"date-time":"2018-02-07T22:49:10Z","timestamp":1518043750000},"page":"e147-e155","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Azacitidine Use for Myeloid Neoplasms"],"prefix":"10.1016","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4498-3865","authenticated-orcid":false,"given":"Riad","family":"El Fakih","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"Komrokji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwan","family":"Shaheen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahad","family":"Almohareb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walid","family":"Rasheed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Hassanein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2018.02.005_bib1","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1158\/1078-0432.CCR-04-2135","article-title":"Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes","volume":"11","author":"Kaminskas","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2018.02.005_bib2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1101\/gad.947102","article-title":"DNA methylation patterns and epigenetic memory","volume":"16","author":"Bird","year":"2002","journal-title":"Genes Dev"},{"key":"10.1016\/j.clml.2018.02.005_bib3","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0022-2836(87)90689-9","article-title":"CpG islands in vertebrate genomes","volume":"196","author":"Gardiner-Garden","year":"1987","journal-title":"J\u00a0Mol Biol"},{"key":"10.1016\/j.clml.2018.02.005_bib4","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1073\/pnas.89.5.1827","article-title":"A\u00a0genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands","volume":"89","author":"Frommer","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clml.2018.02.005_bib5","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1093\/emboj\/17.8.2426","article-title":"Initiation of DNA replication at CpG islands in mammalian chromosomes","volume":"17","author":"Delgado","year":"1998","journal-title":"EMBO J"},{"key":"10.1016\/j.clml.2018.02.005_bib6","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/0092-8674(79)90329-5","article-title":"Methylated and unmethylated DNA compartments in the sea urchin genome","volume":"17","author":"Bird","year":"1979","journal-title":"Cell"},{"key":"10.1016\/j.clml.2018.02.005_bib7","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/0092-8674(90)90015-7","article-title":"High levels of de novo methylation and altered chromatin structure at CpG islands in cell lines","volume":"62","author":"Antequera","year":"1990","journal-title":"Cell"},{"key":"10.1016\/j.clml.2018.02.005_bib8","series-title":"Modified Nucleosides and Cancer","first-page":"202","article-title":"Inhibition of DNA methylation by 5-azacytidine","author":"Jones","year":"1983"},{"key":"10.1016\/j.clml.2018.02.005_bib9","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.1038\/sj.onc.1205699","article-title":"5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy","volume":"21","author":"Christman","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.clml.2018.02.005_bib10","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1093\/nar\/9.12.2933","article-title":"Hemimethylated duplex DNAs prepared from 5-azacytidine-treated cells","volume":"9","author":"Jones","year":"1981","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.clml.2018.02.005_bib11","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1128\/jb.169.4.1537-1546.1987","article-title":"Genetic analysis of the 5-azacytidine sensitivity of Escherichia coli K-12","volume":"169","author":"Bhagwat","year":"1987","journal-title":"J\u00a0Bacteriol"},{"key":"10.1016\/j.clml.2018.02.005_bib12","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0163-7258(94)00053-6","article-title":"The effects of 5-azacytidine and 5-azadeoxycytidine on chromosome structure and function: implications for methylation-associated cellular processes","volume":"65","author":"Haaf","year":"1995","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.clml.2018.02.005_bib13","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1182\/blood.V90.4.1403","article-title":"Hypermethylation of the p15INK4B gene in myelodysplastic syndromes","volume":"90","author":"Uchida","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.005_bib14","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1038\/sj.leu.2403054","article-title":"Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia","volume":"17","author":"Christiansen","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.02.005_bib15","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.exphem.2006.11.005","article-title":"Loss of the tumor suppressor p15Ink4b enhances myeloid progenitor formation from common myeloid progenitors","volume":"35","author":"Rosu-Myles","year":"2007","journal-title":"Exp Hematol"},{"key":"10.1016\/j.clml.2018.02.005_bib16","doi-asserted-by":"crossref","first-page":"25211","DOI":"10.1074\/jbc.M111.235028","article-title":"Aberrant epigenetic and genetic marks are seen in myelodysplastic leukocytes and reveal Dock4 as a candidate pathogenic gene on chromosome 7q","volume":"286","author":"Zhou","year":"2011","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.clml.2018.02.005_bib17","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1600-0609.2011.01715.x","article-title":"Epigenetic dysregulation of GATA1 is involved in myelodysplastic syndromes dyserythropoiesis","volume":"88","author":"Hopfer","year":"2012","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2018.02.005_bib18","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","article-title":"Mutation in TET2 in myeloid cancers","volume":"360","author":"Delhommeau","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2018.02.005_bib19","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ng.621","article-title":"Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders","volume":"42","author":"Ernst","year":"2010","journal-title":"Nat Genet"},{"key":"10.1016\/j.clml.2018.02.005_bib20","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","article-title":"Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation","volume":"18","author":"Figueroa","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2018.02.005_bib21","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1756-8722-5-12","article-title":"Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases","volume":"5","author":"Gelsi-Boyer","year":"2012","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.clml.2018.02.005_bib22","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1038\/leu.2011.44","article-title":"Recurrent DNMT3A mutations in patients with myelodysplastic syndromes","volume":"25","author":"Walter","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.02.005_bib23","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/sj.leu.2402114","article-title":"Nucleoside analogues: mechanisms of drug resistance and reversal strategies","volume":"15","author":"Galmarini","year":"2001","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.02.005_bib24","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1182\/blood-2008-02-140038","article-title":"Mechanisms of resistance to 5-aza-2\u2032-deoxycytidine in human cancer cell lines","volume":"113","author":"Qin","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.005_bib25","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2141.1982.tb08475.x","article-title":"Proposals for the classification of the myelodysplastic syndromes","volume":"51","author":"Bennett","year":"1982","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.02.005_bib26","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1200\/JCO.1999.17.12.3835","article-title":"World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997","volume":"17","author":"Harris","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.02.005_bib27","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.005_bib28","first-page":"297","article-title":"Myelodysplastic syndromes","volume":"1","author":"List","year":"2004","journal-title":"ASH Educ Program Book"},{"key":"10.1016\/j.clml.2018.02.005_bib29","first-page":"3671","article-title":"Report of an international working group to standardize response criteria for myelodysplastic syndromes","volume":"96","author":"Cheson","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.005_bib30","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.005_bib31","unstructured":"Nazha A, Komrokji RS, Barnard J, et\u00a0al. Importance of complete remission on predicting overall survival in patients with lower-risk myelodysplastic syndromes (MDS). Presented at the American Society of Hematology; December 3-6, 2016; San Diego, CA."},{"key":"10.1016\/j.clml.2018.02.005_bib32","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3324\/haematol.2012.074831","article-title":"A\u00a0multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial","volume":"98","author":"Gore","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2018.02.005_bib33","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B","volume":"20","author":"Silverman","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.02.005_bib34","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1200\/JCO.2005.05.4346","article-title":"Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B","volume":"24","author":"Silverman","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.02.005_bib35","first-page":"21","article-title":"Effects of treatment with 5-azacytidine on the in\u00a0vivo and in\u00a0vitro hematopoiesis in patients with myelodysplastic syndromes","volume":"7","author":"Silverman","year":"1993","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.02.005_bib36","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/ajh.2830370207","article-title":"Evaluation of continuous infusion low-dose 5-azacytidine in the treatment of myelodysplastic syndromes","volume":"37","author":"Chitambar","year":"1991","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2018.02.005_bib37","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/sj.leu.2404050","article-title":"Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome","volume":"20","author":"Maslak","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.02.005_bib38","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S0145-2126(02)00028-0","article-title":"Treatment of myelodysplastic syndromes with 5-azacytidine","volume":"26","author":"Gryn","year":"2002","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2018.02.005_bib39","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2018.02.005_bib40","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/cncr.21723","article-title":"Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or higher-risk myelodysplastic syndrome","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2018.02.005_bib41","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1182\/blood.V98.8.2326","article-title":"Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS","volume":"98","author":"de Witte","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.005_bib42","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s002770050285","article-title":"S-HAM induction chemotherapy with or without GM-CSF in patients with high-risk myelodysplastic syndromes","volume":"74","author":"Verbeek","year":"1997","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2018.02.005_bib43","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1182\/blood.V98.13.3575","article-title":"Comparison of idarubicin+ ara-C, fludarabine+ ara-C, and topotecan+ ara-C based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts","volume":"98","author":"Estey","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.005_bib44","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/sj.thj.6200363","article-title":"A\u00a0phase II study of intensive chemotherapy with fludarabine, cytarabine, and mitoxantrone in P glycoprotein-negative high-risk myelodysplastic syndromes","volume":"5","author":"Prebet","year":"2004","journal-title":"Hematol J"},{"key":"10.1016\/j.clml.2018.02.005_bib45","doi-asserted-by":"crossref","first-page":"918","DOI":"10.3324\/haematol.2015.140988","article-title":"A\u00a0randomized phase II trial of azacitidine\u00a0+\/- epoetin-beta in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents","volume":"101","author":"Thepot","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2018.02.005_bib46","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1200\/JCO.2008.17.1058","article-title":"Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes","volume":"27","author":"Lyons","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.02.005_bib47","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/leu.2015.265","article-title":"Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes","volume":"30","author":"Garcia-Manero","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.02.005_bib48","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12878-016-0049-5","volume":"16","author":"Garcia-Manero","year":"2016","journal-title":"BMC Hematol"},{"key":"10.1016\/j.clml.2018.02.005_bib49","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood.V120.21.424.424","article-title":"Safety and efficacy of oral azacitidine (CC-486) administered in extended treatment schedules to patients with lower-risk myelodysplastic syndromes","volume":"120","author":"Garcia-Manero","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.005_bib50","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1182\/blood.V120.21.1337.1337","article-title":"Extended dosing of oral azacitidine (CC-486) for 14 and 21 days provides more effective methylation reversal than a 7-day schedule","volume":"120","author":"Laille","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.005_bib51","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1182\/blood.V126.23.908.908","volume":"126","author":"Sekeres","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.005_bib52","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/cncr.29145","article-title":"Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium","volume":"121","author":"Jabbour","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2018.02.005_bib53","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1002\/cncr.25247","article-title":"Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy","volume":"116","author":"Jabbour","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2018.02.005_bib54","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1200\/JCO.2011.35.8135","article-title":"Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure","volume":"29","author":"Prebet","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.02.005_bib55","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.clml.2013.07.007","article-title":"Poor outcome of patients with myelodysplastic syndrome after azacitidine treatment failure","volume":"13","author":"Duong","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2018.02.005_bib56","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.3324\/haematol.2012.071050","article-title":"Outcome of patients with low-risk myelodysplasia after azacitidine treatment failure","volume":"98","author":"Prebet","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2018.02.005_bib57","first-page":"277","article-title":"Cancer statistics, 2010","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clml.2018.02.005_bib58","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1200\/JCO.2007.15.4245","article-title":"Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group","volume":"27","author":"Buchner","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.02.005_bib59","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1002\/cncr.24373","article-title":"Outcomes and quality of care in acute myeloid leukemia over 40 years","volume":"115","author":"Alibhai","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2018.02.005_bib60","first-page":"62","article-title":"Acute myeloid leukemia","volume":"119","author":"Appelbaum","year":"2001","journal-title":"ASH Educ Program Book"},{"key":"10.1016\/j.clml.2018.02.005_bib61","doi-asserted-by":"crossref","first-page":"e2013050","DOI":"10.4084\/mjhid.2013.050","article-title":"Therapeutic options for patients who are not eligible for intensive chemotherapy","volume":"5","author":"Estey","year":"2013","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.clml.2018.02.005_bib62","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.3324\/haematol.2012.066100","article-title":"Survival for older patients with acute myeloid leukemia: a population-based study","volume":"97","author":"Oran","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2018.02.005_bib63","doi-asserted-by":"crossref","first-page":"7473","DOI":"10.1073\/pnas.1002650107","article-title":"Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine","volume":"107","author":"Blum","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clml.2018.02.005_bib64","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1200\/JCO.2009.23.9178","article-title":"Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia","volume":"28","author":"Cashen","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.02.005_bib65","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1182\/blood-2003-03-0687","article-title":"Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2-deoxycytidine (decitabine) in hematopoietic malignancies","volume":"103","author":"Issa","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.005_bib66","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3324\/haematol.2011.048231","article-title":"A\u00a0multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy","volume":"97","author":"L\u00fcbbert","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2018.02.005_bib67","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1182\/blood.V118.21.2614.2614","article-title":"Efficacy of frontline 5-azacytidine in older AML patient unfit for chemotherapy","volume":"118","author":"Bories","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.005_bib68","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21792","article-title":"Decitabine improves patient outcomes in myelodysplastic syndromes","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2018.02.005_bib69","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1200\/JCO.2009.23.8329","article-title":"Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia","volume":"28","author":"Fenaux","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.02.005_bib70","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1182\/blood.V124.21.10.10","article-title":"Azacitidine (AZA) versus conventional care regimens (CCR) in older patients with newly diagnosed acute myeloid leukemia (> 30% bone marrow blasts) with morphologic dysplastic changes: a subgroup analysis of the AZA-AML-001 trial","volume":"124","author":"Seymour","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.005_bib71","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.005_bib72","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"Dohner","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.005_bib73","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.leukres.2014.12.013","article-title":"Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome prediction","volume":"39","author":"Ramos","year":"2015","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2018.02.005_bib74","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/ajh.23654","article-title":"Azacitidine in untreated acute myeloid leukemia: a report on 149 patients","volume":"89","author":"Thepot","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2018.02.005_bib75","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1756-8722-6-32","article-title":"Azacitidine in patients with WHO-defined AML: results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group","volume":"6","author":"Pleyer","year":"2013","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.clml.2018.02.005_bib76","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","article-title":"Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia","volume":"30","author":"Kantarjian","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.02.005_bib77","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.leukres.2013.03.022","article-title":"Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blasts","volume":"37","author":"Van der Helm","year":"2013","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2018.02.005_bib78","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.3324\/haematol.2012.065151","article-title":"Transfusion independence and survival in patients with acute myeloid leukemia treated with 5-azacytidine","volume":"97","author":"Gavillet","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2018.02.005_bib79","doi-asserted-by":"crossref","first-page":"4840","DOI":"10.1182\/blood-2012-06-436055","article-title":"Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia","volume":"120","author":"Quintas-Cardama","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.005_bib80","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMoa1605949","article-title":"TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes","volume":"375","author":"Welch","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2018.02.005_bib81","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1182\/blood.V122.21.1445.1445","article-title":"Comparison of epigenetic versus intensive chemotherapy for newly diagnosed acute myeloid leukemia patients\u00a0\u226560 years old: the Roswell Park experience","volume":"122","author":"Gandhi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.005_bib82","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1756-8722-6-29","article-title":"Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patients","volume":"6","author":"van der Helm","year":"2013","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.clml.2018.02.005_bib83","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.3109\/10428194.2012.762093","article-title":"Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia","volume":"54","author":"Ritchie","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2018.02.005_bib84","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00277-013-1940-9","article-title":"Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML)","volume":"93","author":"Tawfik","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2018.02.005_bib85","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/ajh.24087","article-title":"A\u00a0multicenter, phase II study of maintenance azacitidine in older patients with acute myeloid leukemia in complete remission after induction chemotherapy","volume":"90","author":"Griffin","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2018.02.005_bib86","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/bjh.13281","article-title":"Maintenance lenalidomide in combination with 5-azacitidine as post-remission therapy for acute myeloid leukaemia","volume":"169","author":"Wei","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.02.005_bib87","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2217\/fon.15.326","article-title":"Design of the randomized, phase III, QUAZAR AML maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia","volume":"12","author":"Roboz","year":"2016","journal-title":"Future Oncol"},{"key":"10.1016\/j.clml.2018.02.005_bib88","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1182\/blood.V126.23.452.452","article-title":"CC-486 (oral azacitidine) monotherapy in patients with acute myeloid leukemia (AML)","volume":"126","author":"Savona","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.005_bib89","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1038\/leu.2012.153","article-title":"A\u00a0randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission","volume":"26","author":"Boumber","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.02.005_bib90","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/ajh.23498","article-title":"Outcome of older patients with acute myeloid leukemia in first relapse","volume":"88","author":"Sarkozy","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2018.02.005_bib91","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.leukres.2014.11.009","article-title":"Azacitidine for the treatment of relapsed and refractory AML in older patients","volume":"39","author":"Itzykson","year":"2015","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2018.02.005_bib92","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.clml.2013.09.014","article-title":"Patterns of infection in patients with myelodysplastic syndromes and acute myeloid leukemia receiving azacitidine as salvage therapy. Implications for primary antifungal prophylaxis","volume":"14","author":"Falantes","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2018.02.005_bib93","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2011.37.9743","article-title":"Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial","volume":"30","author":"Faderl","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.02.005_bib94","unstructured":"Stahl M, Podoltsev NA, DeVeaux M, et\u00a0al. The use of hypomethylating agents (HMAs) in patients with relapsed and refractory acute myeloid leukemia (RR-AML): clinical outcomes and their predictors in a large international patient cohort. Presented at the American Society of Hematology; December 3-6, 2016; San Diego, CA."},{"key":"10.1016\/j.clml.2018.02.005_bib95","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3324\/haematol.2013.096545","article-title":"Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase 1\/2 study","volume":"99","author":"Walter","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2018.02.005_bib96","doi-asserted-by":"crossref","first-page":"34","DOI":"10.18632\/oncotarget.106","article-title":"Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome","volume":"1","author":"Raffoux","year":"2010","journal-title":"Oncotarget"},{"key":"10.1016\/j.clml.2018.02.005_bib97","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1182\/blood-2013-01-480228","article-title":"Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation","volume":"121","author":"Ravandi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.005_bib98","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3109\/10428194.2011.606382","article-title":"Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I\/II study","volume":"53","author":"Al-Ali","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2018.02.005_bib99","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/cncr.26354","article-title":"Azacitidine for the treatment of patients with acute myeloid leukemia","volume":"118","author":"Maurillo","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2018.02.005_bib100","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1182\/blood.V120.21.3584.3584","volume":"120","author":"Nand","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.005_bib101","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1182\/blood.V126.23.327.327","article-title":"A\u00a0phase 1b study of venetoclax (ABT-199\/GDC-0199) in combination with decitabine or azacitidine in treatment-naive patients with acute myelogenous leukemia who are\u00a0\u2265 to 65 years and not eligible for standard induction therapy","volume":"126","author":"Dinardo","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.005_bib102","doi-asserted-by":"crossref","first-page":"591","DOI":"10.3324\/haematol.2012.076414","article-title":"Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia","volume":"98","author":"Pollyea","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2018.02.005_bib103","doi-asserted-by":"crossref","unstructured":"Montalban-Bravo G, Huang X, Jabbour EJ, et\u00a0al. A phase II clinical trial of azacitidine and vorinostat for patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) with poor performance status, comorbidities, other active malignancies or organ dysfunction not eligible for conventional clinical trials. Presented at the American Society of Hematology\u00a02016.","DOI":"10.1182\/blood.V128.22.1999.1999"},{"key":"10.1016\/j.clml.2018.02.005_bib104","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1182\/blood.V118.21.608.608","volume":"118","author":"Garcia-Manero","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.005_bib105","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood.V126.23.453.453","article-title":"Final results from a phase 2 study of pracinostat in combination with azacitidine in elderly patients with acute myeloid leukemia (AML)","volume":"126","author":"Garcia-Manero","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.005_bib106","doi-asserted-by":"crossref","first-page":"9612","DOI":"10.18632\/oncotarget.3324","article-title":"Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS\/AML patients: a rationale for combined targeting of PD-1 and DNA methylation","volume":"6","author":"Orskov","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.clml.2018.02.005_bib107","doi-asserted-by":"crossref","unstructured":"Daver N, Basu S, Garcia-Manero G, et\u00a0al. Phase IB\/II study of nivolumab in combination with azacytidine (AZA) in patients (pts) with relapsed acute myeloid leukemia (AML). Presented at the American Society of Hematology\u00a02016.","DOI":"10.1182\/blood.V128.22.763.763"},{"key":"10.1016\/j.clml.2018.02.005_bib108","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1182\/blood.V118.21.2612.2612","article-title":"5-Azacytidine versus intensive chemotherapy or BSC in elderly (> 60 years) acute myeloid leukemia patients. A retrospective analysis","volume":"118","author":"Serrano","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.005_bib109","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1002\/cncr.22204","article-title":"Treatment of acute myelogenous leukemia with outpatient azacitidine","volume":"107","author":"Sudan","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2018.02.005_bib110","doi-asserted-by":"crossref","first-page":"4533","DOI":"10.1200\/JCO.2012.44.3499","article-title":"Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Societe Francaise de Greffe de Moelle et de Therapie-Cellulaire and the Groupe-Francophone des Myelodysplasies","volume":"30","author":"Damaj","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.02.005_bib111","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.bbmt.2014.02.008","article-title":"Pretransplantation 5-azacitidine in high-risk myelodysplastic syndrome","volume":"20","author":"Nishihori","year":"2014","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.clml.2018.02.005_bib112","doi-asserted-by":"crossref","first-page":"5420","DOI":"10.1002\/cncr.25500","article-title":"Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome","volume":"116","author":"De Lima","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2018.02.005_bib113","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.bbmt.2015.09.004","article-title":"Tolerability and clinical activity of post-transplantation azacitidine in patients allografted for acute myeloid leukemia treated on the RICAZA trial","volume":"22","author":"Craddock","year":"2016","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.clml.2018.02.005_bib114","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1182\/blood-2009-11-249474","article-title":"Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia","volume":"116","author":"Goodyear","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.005_bib115","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1182\/blood-2011-09-377044","article-title":"Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)","volume":"119","author":"Goodyear","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.005_bib116","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/leu.2011.234","article-title":"Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial","volume":"26","author":"Platzbecker","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.02.005_bib117","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1002\/cncr.24198","article-title":"Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia","volume":"115","author":"Jabbour","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2018.02.005_bib118","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.bbmt.2010.10.008","article-title":"5-Azacytidine as salvage treatment in relapsed myeloid tumors after allogeneic bone marrow transplantation","volume":"17","author":"Bolanos-Meade","year":"2011","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.clml.2018.02.005_bib119","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/bmt.2015.10","article-title":"5-Azacytidine and DLI can induce long-term remissions in AML patients relapsed after allograft","volume":"50","author":"Steinmann","year":"2015","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.clml.2018.02.005_bib120","doi-asserted-by":"crossref","first-page":"879","DOI":"10.3324\/haematol.2015.140996","article-title":"Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia","volume":"101","author":"Craddock","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2018.02.005_bib121","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.bbmt.2014.12.016","article-title":"Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions a retrospective multicenter analysis from the German Cooperative Transplant Study Group","volume":"21","author":"Schroeder","year":"2015","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.clml.2018.02.005_bib122","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.bbmt.2016.03.023","article-title":"Chemotherapy versus hypomethylating agents for the treatment of relapsed acute myeloid leukemia and myelodysplastic syndrome after allogeneic stem cell transplant","volume":"7","author":"Motabi","year":"2016","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.clml.2018.02.005_bib123","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1084\/jem.20070109","article-title":"CREB\/ATF-dependent T cell receptor-induced FoxP3 gene expression: a role for DNA methylation","volume":"204","author":"Kim","year":"2007","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.clml.2018.02.005_bib124","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.bbrc.2008.03.131","article-title":"Induction of MHC class I-related chain B (MICB) by 5-aza-2-deoxycytidine","volume":"370","author":"Tang","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.clml.2018.02.005_bib125","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1016\/j.transproceed.2009.02.101","article-title":"Use of epigenetic modification to induce FOXP3 expression in naive T cells","volume":"41","author":"Moon","year":"2009","journal-title":"Transpl Proc"},{"key":"10.1016\/j.clml.2018.02.005_bib126","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1038\/leu.2013.64","article-title":"Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation","volume":"27","author":"Schroeder","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.02.005_bib127","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1182\/blood-2014-06-582809","article-title":"TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients","volume":"124","author":"Bejar","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.005_bib128","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/bjh.12884","article-title":"Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes","volume":"166","author":"Zeidan","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.02.005_bib129","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1182\/blood-2010-06-289280","article-title":"Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine","volume":"117","author":"Itzykson","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.005_bib130","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.1365-2141.2011.08893.x","volume":"155","author":"van der Helm","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.02.005_bib131","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s11899-013-0172-3","article-title":"There\u2019s risk, and then there\u2019s RISK: the latest clinical prognostic risk stratification models in myelodysplastic syndromes","volume":"8","author":"Zeidan","year":"2013","journal-title":"Curr Hematol Malig Rep"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265017315860?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265017315860?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:30:40Z","timestamp":1761870640000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265017315860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":131,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S2152265017315860"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2018.02.005","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Azacitidine Use for Myeloid Neoplasms","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2018.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}